TLR4-Based Immunotherapeutics in Cancer: A Review of the Achievements and Shortcomings
The DOI matches its Crossref record; 181 of the 181 references it cites were found in a registry or an index.
Abstract
Toll-like Receptor 4 (TLR4) agonists have had a long journey in the field of cancer immunotherapy. Nevertheless, despite the remarkable number of the TLR4 ligands that have gone through various preclinical and clinical stages, only two (Bacillus Calmette-Guérin (BCG) and monophosphoryl lipid A (MPLA)) have hitherto obtained the FDA approval for clinical application in cancer treatment. This paper provides a comprehensive review of the TLR4 agonists' journey as cancer active immunotherapeutics. Following a brief discussion of the rationale behind the use of TLR ligands in cancer immunotherapy, we will initially focus on the forerunner of the TLR4 agonists, bacterial lipopolysaccharide (LPS). Within this context, the potentials and shortcomings of immunotherapy with this agent will be addressed, the strategies that have been devised to enhance the associated therapeutic outcome will be discussed, and the consequent achievements and shortcomings will be summarized. Subsequently, further and perhaps less well-known, molecular, bacterial, and viral TLR4 agonists with potential for cancer immunotherapy will be introduced, and if present, the outcome of the preclinical and clinical investigations of these agents will be reviewed. Finally, a look will be cast upon the promising souvenirs of the relatively new arena of nanotechnology, where TLR4 activating nanoparticulate systems will be proposed as potential candidates for the future development of this field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammatory caspases are innate immune receptors for intracellular LPS
Shi, J., Zhao, Y., Wang, Y., Gao, W., Ding, J., Li, P., Hu, L., & Shao, F. (2014) · Nature · doi:10.1038/nature13683 · Cited by 2,285
Terzić, J., Grivennikov, S., Karin, E., & Karin, M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.058 · Cited by 1,974
Tumour necrosis factor and cancer
Balkwill, F. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2628 · Cited by 1,915
Novel Signal Transduction Pathway Utilized by Extracellular HSP70
Asea, A., Rehli, M., Kabingu, E., Boch, J. A., Baré, O., Auron, P. E., Stevenson, M. A., & Calderwood, S. K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200497200 · Cited by 1,510
The Extra Domain A of Fibronectin Activates Toll-like Receptor 4
Okamura, Y., Watari, M., Jerud, E. S., Young, D. W., Ishizaka, S. T., Rose, J., Chow, J. C., & Strauss, J. F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100099200 · Cited by 1,216
Minireview: Nanoparticles and the Immune System
Zolnik, B. S., González-Fernández, A., Sadrieh, N., & Dobrovolskaia, M. A. (2010) · Endocrinology · doi:10.1210/en.2009-1082 · Cited by 914
Toll-like receptor function and signaling
Kaisho, T., & Akira, S. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.02.023 · Cited by 898
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L. (2007) · Nature Medicine · doi:10.1038/nm1589 · Cited by 869
Krug, A., Towarowski, A., Britsch, S., Rothenfusser, S., Hornung, V., Bals, R., Giese, T., Engelmann, H., Endres, S., Krieg, A. M., et al. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(2001010)31:10<3026::aid-immu3026>3.0.co;2-h · Cited by 786
Cario, E., Rosenberg, I. M., Brandwein, S. L., Beck, P. L., Reinecker, H.-C., & Podolsky, D. K. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.2.966 · Cited by 751
An Agonist of Toll-Like Receptor 5 Has Radioprotective Activity in Mouse and Primate Models
Burdelya, L. G., Krivokrysenko, V. I., Tallant, T. C., Strom, E., Gleiberman, A. S., Gupta, D., Kurnasov, O. V., Fort, F. L., Osterman, A. L., DiDonato, J. A., et al. (2008) · Science · doi:10.1126/science.1154986 · Cited by 705
Immunotherapy of Tumors with Autologous Tumor-Derived Heat Shock Protein Preparations
Tamura, Y., Peng, P., Liu, K., Daou, M., & Srivastava, P. K. (1997) · Science · doi:10.1126/science.278.5335.117 · Cited by 680
Toll-Like Receptor-4 Promotes the Development of Colitis-Associated Colorectal Tumors
Fukata, M., Chen, A., Vamadevan, A. S., Cohen, J., Breglio, K., Krishnareddy, S., Hsu, D., Xu, R., Harpaz, N., Dannenberg, A. J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.09.008 · Cited by 621
Heat shock protein 70-associated peptides elicit specific cancer immunity.
Udono, H., & Srivastava, P. K. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.4.1391 · Cited by 621
Lamm, D. L., Blumenstein, B. A., Crawford, E. D., Montie, J. E., Scardino, P., Grossman, H. B., Stanisic, T. H., Smith, J. A., Sullivan, J., Sarosdy, M. F., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110243251703 · Cited by 605
Characterization of Heme as Activator of Toll-like Receptor 4
Figueiredo, R. T., Fernandez, P. L., Mourao-Sa, D. S., Porto, B. N., Dutra, F. F., Alves, L. S., Oliveira, M. F., Oliveira, P. L., Graça-Souza, A. V., & Bozza, M. T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610737200 · Cited by 576
Edwards, A. D., Diebold, S. S., Slack, E. M. C., Tomizawa, H., Hemmi, H., Kaisho, T., Akira, S., & Sousa, C. R. E. (2003) · European Journal of Immunology · doi:10.1002/eji.200323797 · Cited by 551
Kedmi, R., Ben-Arie, N., & Peer, D. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.05.027 · Cited by 546
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial
Vermorken, J. B., Claessen, A. M., van Tinteren, H., Gall, H. E., Ezinga, R., Meijer, S., Scheper, R. J., Meijer, C. J., Bloemena, E., Ransom, J. H., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07186-4 · Cited by 504
Involvement of Toll-Like Receptor 4 in Innate Immunity to Respiratory Syncytial Virus
Haynes, L. M., Moore, D. D., Kurt-Jones, E. A., Finberg, R. W., Anderson, L. J., & Tripp, R. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.22.10730-10737.2001 · Cited by 496
Nanoparticle-Based Immunotherapy for Cancer
Shao, K., Singha, S., Clemente-Casares, X., Tsai, S., Yang, Y., & Santamaria, P. (2015) · ACS Nano · doi:10.1021/nn5062029 · Cited by 470
Coley's toxins, tumor necrosis factor and cancer research: A historical perspective
Wiemann, B., & Starnes, C. O. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90023-x · Cited by 467
Endotoxin and Double Stranded RNA render Macrophages Cytotoxic
ALEXANDER, P., & EVANS, R. (1971) · Nature New Biology · doi:10.1038/newbio232076a0 · Cited by 438
A potential role of macrophage activation in the treatment of cancer
Klimp, A. H., de Vries, E. G. E., Scherphof, G. L., & Daemen, T. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00203-7 · Cited by 360
Schaefer, T. M., Desouza, K., Fahey, J. V., Beagley, K. W., & Wira, C. R. (2004) · Immunology · doi:10.1111/j.1365-2567.2004.01898.x · Cited by 341
Zhou, G. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2003.12.002 · Cited by 339
COOPER, C. L., DAVIS, H. L., MORRIS, M. L., EFLER, S. M., ADHAMI, M. A., KRIEG, A. M., CAMERON, D. W., & HEATHCOTE, J. (2004) · Journal of Clinical Immunology · doi:10.1007/s10875-004-6244-3 · Cited by 330
Immunomodulation and antitumor activity of κ-carrageenan oligosaccharides
YUAN, H., SONG, J., LI, X., LI, N., & DAI, J. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.11.032 · Cited by 324
Coler, R. N., Bertholet, S., Moutaftsi, M., Guderian, J. A., Windish, H. P., Baldwin, S. L., Laughlin, E. M., Duthie, M. S., Fox, C. B., Carter, D., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016333 · Cited by 312
Toll-Like Receptor Agonists in Cancer Therapy
Adams, S. (2009) · Immunotherapy · doi:10.2217/imt.09.70 · Cited by 310
Toll-like receptor signaling in cell proliferation and survival
Li, X., Jiang, S., & Tapping, R. I. (2010) · Cytokine · doi:10.1016/j.cyto.2009.08.010 · Cited by 309
Evidence for IFN-gamma as a mediator of the lethality of endotoxin and tumor necrosis factor-alpha
Doherty, G. M., Lange, J. R., Langstein, H. N., Alexander, H. R., Buresh, C. M., & Norton, J. A. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.5.1666 · Cited by 300
Berd, D., Maguire, H. C., McCue, P., & Mastrangelo, M. J. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.11.1858 · Cited by 300
Anti-tumor and immunoregulatory activities of Ganoderma lucidum and its possible mechanisms.
Zhi-binLIN, & Hui-naZHANG (2004) · PubMed · Cited by 285
Gao, Y., Zhou, S., Jiang, W., Huang, M., & Dai, X. (2003) · Immunological Investigations · doi:10.1081/imm-120022979 · Cited by 283
Harris, J. E., Ryan, L., Hoover, H. C., Stuart, R. K., Oken, M. M., Benson, A. B., Mansour, E., Haller, D. G., Manola, J., & Hanna, M. G. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.148 · Cited by 273
Graphene Oxide Induces Toll-like Receptor 4 (TLR4)-Dependent Necrosis in Macrophages
Qu, G., Liu, S., Zhang, S., Wang, L., Wang, X., Sun, B., Yin, N., Gao, X., Xia, T., Chen, J.-J., et al. (2013) · ACS Nano · doi:10.1021/nn402330b · Cited by 273
Human endotoxemia as a model of systemic inflammation
Andreasen, A., Krabbe, K., Krogh-Madsen, R., Taudorf, S., Pedersen, B., & Moller, K. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708784872393 · Cited by 271
Testori, A., Richards, J., Whitman, E., Mann, G. B., Lutzky, J., Camacho, L., Parmiani, G., Tosti, G., Kirkwood, J. M., Hoos, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9941 · Cited by 257
Hold, G. L., Rabkin, C. S., Chow, W., Smith, M. G., Gammon, M. D., Risch, H. A., Vaughan, T. L., McColl, K. E. L., Lissowska, J., Zatonski, W., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.12.026 · Cited by 256
The role of Toll-like receptors in chronic inflammation
Drexler, S. K., & Foxwell, B. M. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.10.009 · Cited by 248
Harmey, J. H., Bucana, C. D., Lu, W., Byrne, A. M., McDonnell, S., Lynch, C., Bouchier‐Hayes, D., & Dong, Z. (2002) · International Journal of Cancer · doi:10.1002/ijc.10632 · Cited by 247
Krause, S. W., Gastpar, R., Andreesen, R., Gross, C., Ullrich, H., Thonigs, G., Pfister, K., & Multhoff, G. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0683 · Cited by 246
Janetzki, S., Palla, D., Rosenhauer, V., Lochs, H., Lewis, J. J., & Srivastava, P. K. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001015)88:2<232::aid-ijc14>3.0.co;2-8 · Cited by 246
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
Vacchelli, E., Galluzzi, L., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.20931 · Cited by 244
Ganoderma lucidum extract induces cell cycle arrest and apoptosis in MCF‐7 human breast cancer cell
Hu, H., Ahn, N., Yang, X., Lee, Y., & Kang, K. (2002) · International Journal of Cancer · doi:10.1002/ijc.10707 · Cited by 232
Wang, S., Campos, J., Gallotta, M., Gong, M., Crain, C., Naik, E., Coffman, R. L., & Guiducci, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608555113 · Cited by 231
Wen, Z.-S., Xu, Y.-L., Zou, X.-T., & Xu, Z.-R. (2011) · Marine Drugs · doi:10.3390/md9061038 · Cited by 231
Szajnik, M., Szczepanski, M. J., Czystowska, M., Elishaev, E., Mandapathil, M., Nowak-Markwitz, E., Spaczynski, M., & Whiteside, T. L. (2009) · Oncogene · doi:10.1038/onc.2009.289 · Cited by 226
Giaccone, G., Debruyne, C., Felip, E., Chapman, P. B., Grant, S. C., Millward, M., Thiberville, L., D'addario, G., Coens, C., Rome, L. S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.17.186 · Cited by 223
Adams, S., Kozhaya, L., Martiniuk, F., Meng, T.-C., Chiriboga, L., Liebes, L., Hochman, T., Shuman, N., Axelrod, D., Speyer, J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1149 · Cited by 222
Suzuki, M., Hisamatsu, T., & Podolsky, D. K. (2003) · Infection and Immunity · doi:10.1128/iai.71.6.3503-3511.2003 · Cited by 218
Schmaußer, B., Andrulis, M., Endrich, S., Müller-Hermelink, H.-K., & Eck, M. (2005) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2005.02.009 · Cited by 208
Monophosphoryl Lipid A (MPL) as an Adjuvant for Anti-Cancer Vaccines: Clinical Results
Cluff, C. W. (2009) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4419-1603-7_10 · Cited by 205
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy
Galluzzi, L., Vacchelli, E., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.20696 · Cited by 195
Maeda, Y., & Kimura, Y. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.4.945 · Cited by 190
Borghaei, H., Smith, M. R., & Campbell, K. S. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.09.067 · Cited by 183
Innate immunity and toll-like receptors: clinical implications of basic science research
Abreu, M. T., & Arditi, M. (2004) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2004.01.057 · Cited by 182
VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
Lu, H., Dietsch, G. N., Matthews, M.-A. H., Yang, Y., Ghanekar, S., Inokuma, M., Suni, M., Maino, V. C., Henderson, K. E., Howbert, J. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1625 · Cited by 176
Toll-Like Receptor 4 Activation in Cancer Progression and Therapy
Oblak, A., & Jerala, R. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/609579 · Cited by 175
Smirnov, D., Schmidt, J. J., Capecchi, J. T., & Wightman, P. D. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.061 · Cited by 174
Held, T. K., Weihua, X., Yuan, L., Kalvakolanu, D. V., & Cross, A. S. (1999) · Infection and Immunity · doi:10.1128/iai.67.1.206-212.1999 · Cited by 171
TLR4/MD-2 activation by a synthetic agonist with no similarity to LPS
Wang, Y., Su, L., Morin, M. D., Jones, B. T., Whitby, L. R., Surakattula, M. M. R. P., Huang, H., Shi, H., Choi, J. H., Wang, K.-W., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525639113 · Cited by 169
Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists
Peri, F., & Piazza, M. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.05.014 · Cited by 162
Hsu, H.-Y., Hua, K.-F., Lin, C.-C., Lin, C.-H., Hsu, J., & Wong, C.-H. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.10.5989 · Cited by 161
Chronic inflammation, immunosuppression and cancer: New insights and outlook
Baniyash, M. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.12.002 · Cited by 160
Luo, M., Shao, B., Nie, W., Wei, X., Li, Y.-L., Wang, B., He, Z., Liang, X., Ye, T., & Wei, Y.-Q. (2015) · Scientific Reports · doi:10.1038/srep11062 · Cited by 157
Thomas, K. W., Monick, M. M., Staber, J. M., Yarovinsky, T., Carter, A. B., & Hunninghake, G. W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108107200 · Cited by 151
Receptor-mediated stimulatory effect of oligochitosan in macrophages.
Feng, J., Zhao, L., & Yu, Q.-Q. (2004) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2004.03.048 · Cited by 149
UYLDEGROOT, C., Vermorken, J. B., HannaJr., M. G., Verboom, P., Groot, M., Bonsel, G. J., Meijer, C. J. L. M., & Pinedo, H. M. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.015 · Cited by 146
Pidgeon, G. P., Harmey, J. H., Kay, E., Costa, M. D., Redmond, H. P., & Bouchier-Hayes, D. J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6694369 · Cited by 146
Cancer relapse under chemotherapy: Why TLR2/4 receptor agonists can help
Garay, R. P., Viens, P., Bauer, J., Normier, G., Bardou, M., Jeannin, J., & Chiavaroli, C. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.02.018 · Cited by 145
The application of Toll like receptors for cancer therapy
So, E. Y., & Ouchi, T. (2010) · International Journal of Biological Sciences · doi:10.7150/ijbs.6.675 · Cited by 144
Uto, T., Akagi, T., Yoshinaga, K., Toyama, M., Akashi, M., & Baba, M. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.03.052 · Cited by 141
Huang, Z. D., Yang, Y., Jiang, Y., Shao, J., Sun, X., Chen, J., Dong, L., & Zhang, J. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.09.062 · Cited by 140
Wang, J. H., Manning, B. J., Wu, Q. D., Blankson, S., Bouchier-Hayes, D., & Redmond, H. P. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.2.795 · Cited by 139
Petersen, L. K., Ramer‐Tait, A. E., Broderick, S., Kong, C.-S., Ulery, B. D., Rajan, K., Wannemuehler, M. J., & Narasimhan, B. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.05.063 · Cited by 138
Message in a bottle: Role of the 70‐kDa heat shock protein family in anti‐tumor immunity
Calderwood, S. K., Thériault, J. R., & Gong, J. (2005) · European Journal of Immunology · doi:10.1002/eji.200535002 · Cited by 137
Toll-like receptors, wound healing, and carcinogenesis
Kluwe, J., Mencin, A., & Schwabe, R. F. (2009) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0426-z · Cited by 134
CpG oligodeoxynucleotides as immunotherapy in cancer
Jahrsdörfer, B., & Weiner, G. J. (2008) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2007.11.003 · Cited by 132
Bhattacharyya, S., Liu, H., Zhang, Z., Jam, M., Dudeja, P. K., Michel, G., Linhardt, R. J., & Tobacman, J. K. (2010) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2009.07.002 · Cited by 120
Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state
Fujimoto, T., Duda, R. B., Szilvasi, A., Chen, X., Mai, M., & O'Donnell, M. A. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.12.5619 · Cited by 118
Facets of heat shock protein 70 show immunotherapeutic potential
Todryk, S. M., Gough, M. J., & Pockley, A. G. (2003) · Immunology · doi:10.1046/j.1365-2567.2003.01725.x · Cited by 118
Levine, A. S., Sivulich, M., Wiernik, P. H., & Levy, H. B. (1979) · PubMed · Cited by 117
Lundin, J. I., & Checkoway, H. (2009) · Environmental Health Perspectives · doi:10.1289/ehp.0800439 · Cited by 115
Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients.
Engelhardt, R., Mackensen, A., & Galanos, C. (1991) · PubMed · Cited by 114
Lindemans, C. A., Coffer, P. J., Schellens, I. M. M., de Graaff, P. M. A., Kimpen, J. L. L., & Koenderman, L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.9.5529 · Cited by 114
Wang, Q., Zhou, Z., Tang, S., & Guo, Z. (2012) · ACS Chemical Biology · doi:10.1021/cb200358r · Cited by 114
Toll-like receptor 2 mediates invasion via activating NF-κB in MDA-MB-231 breast cancer cells
Xie, W., Wang, Y., Huang, Y., Yang, H., Wang, J., & Hu, Z. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.01.009 · Cited by 112
Uehori, J., Fukase, K., Akazawa, T., Uematsu, S., Akira, S., Funami, K., Shingai, M., Matsumoto, M., Azuma, I., Toyoshima, K., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.7096 · Cited by 108
Zaks‐Zilberman, M., Zaks, T. Z., & Vogel, S. N. (2001) · Cytokine · doi:10.1006/cyto.2001.0935 · Cited by 106
Lasarte, J. J., Casares, N., Gorraiz, M., Hervás-Stubbs, S., Arribillaga, L., Mansilla, C., Durantez, M., Llopiz, D., Sarobe, P., Borrás-Cuesta, F., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.2.748 · Cited by 103
Dunne, A., Marshall, N. A., & Mills, K. H. G. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.03.004 · Cited by 98
DiC14‐amidine cationic liposomes stimulate myeloid dendritic cells through Toll‐like receptor 4
Tanaka, T., Legat, A., Adam, E., Steuve, J., Gatot, J., Vandenbranden, M., Ulianov, L., Lonez, C., Ruysschaert, J., Muraille, E., et al. (2008) · European Journal of Immunology · doi:10.1002/eji.200737998 · Cited by 98
Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer
Otto, F., Schmid, P., Mackensen, A., Wehr, U., Seiz, A., Braun, M., Galanos, C., Mertelsmann, R., & Engelhardt, R. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00186-4 · Cited by 97
From Secretome Analysis to Immunology
VILLIERS, C. L., Chevallet, M., Diemer, H., Couderc, R., Freitas, H., DORSSELAER, A. V., Marche, P. N., & Rabilloud, T. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800589-mcp200 · Cited by 93
Tsuji, R. F., Hoshino, K., Noro, Y., Tsuji, N. M., Kurokawa, T., Masuda, T., Akira, S., & Nowak, B. (2003) · Clinical & Experimental Allergy · doi:10.1046/j.1365-2222.2003.01575.x · Cited by 93
Ganoderma lucidum extract inhibits proliferation of SW 480 human colorectal cancer cells.
Xie, J., Wang, C. Z., Wicks, S., Yin, J., Kong, J., Li, J., Li, Y. C., & Yuan, C. (2006) · PubMed · Cited by 89
Pantel, A. R., Cheong, C., Dandamudi, D. B., Shrestha, E., Mehandru, S., Brane, L., Ruane, D., Teixeira, A., Bozzacco, L., Steinman, R. M., et al. (2011) · European Journal of Immunology · doi:10.1002/eji.201141855 · Cited by 87
Bourquin, C., Hotz, C., Noerenberg, D., Voelkl, A., Heidegger, S. M., Roetzer, L. C., Storch, B., Sandholzer, N., Wurzenberger, C., Anz, D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3903 · Cited by 86
Resiquimod, a topical drug for viral skin lesions and skin cancer
Meyer, T., Surber, C., French, L. E., & Stockfleth, E. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.749236 · Cited by 86
Grimm, M. R., Kim, M., Rosenwald, A., Heemann, U. W., Germer, C., Waaga-Gasser, A. M., & Gasser, M. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.07.017 · Cited by 86
Berendt, M. J., North, R. J., & Kirstein, D. P. (1978) · The Journal of Experimental Medicine · doi:10.1084/jem.148.6.1560 · Cited by 84
Lung Cancer Risk Among Female Textile Workers Exposed to Endotoxin
Astrakianakis, G., Seixas, N. S., Ray, R., Camp, J. E., Gao, D. L., Feng, Z., Li, W., Wernli, K. J., Fitzgibbons, E. D., Thomas, D. B., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk063 · Cited by 84
Theodoropoulos, G. E., Saridakis, V., Karantanos, T., Michalopoulos, N. V., Zagouri, F., Kontogianni, P., Lymperi, M., Gazouli, M., & Zografos, G. (2012) · The Breast · doi:10.1016/j.breast.2012.04.001 · Cited by 84
Lin, Y., Liang, Y., Tseng, Y.-S., Huang, H., Chou, S., Hseu, R., Huang, C., & Chiang, B. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0708441 · Cited by 84
Phase-I study of intravenous modified lipid A
Vosika, G. J., Barr, C. E., & Gilbertson, D. (1984) · Cancer Immunology Immunotherapy · doi:10.1007/bf00205743 · Cited by 84
Heat Shock Proteins, Autoimmunity, and Cancer Treatment
Calderwood, S. K., Stevenson, M. A., & Murshid, A. (2012) · Autoimmune Diseases · doi:10.1155/2012/486069 · Cited by 83
Aggregation behavior and size of lipopolysaccharide from Escherichia coli O55:B5
Bergstrand, A., Svanberg, C., Langton, M., & Nydén, M. (2006) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2006.06.007 · Cited by 75
Dual character of Toll-like receptor signaling: Pro-tumorigenic effects and anti-tumor functions
Yu, L., Wang, L., & Chen, S. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.10.006 · Cited by 75
Maehara, Y., Okuyama, T., Kakeji, Y., Baba, H., Furusawa, M., & Sugimachi, K. (1994) · The American Journal of Surgery · doi:10.1016/s0002-9610(05)80068-6 · Cited by 74
Wang, C., Zhuang, Y., Zhang, Y., Luo, Z., Gao, N., Li, P., Pan, H., Cai, L., & Ma, Y. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.05.027 · Cited by 73
ENDOTOXINS, COTTON DUST, AND CANCER
Enterline, P., Keleti, G., Sykora, J., & Lange, J. (1985) · The Lancet · doi:10.1016/s0140-6736(85)90861-x · Cited by 72
Poly(methyl vinyl ether-co-maleic anhydride) nanoparticles as innate immune system activators
Camacho, A. I., Martins, R. D. C., Tamayo, I., de Souza, J., Lasarte, J. J., Mansilla, C., Esparza, I., Irache, J. M., & Gamazo, C. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.072 · Cited by 72
Madonna, G. S., Peterson, J. E., Ribi, E. E., & Vogel, S. N. (1986) · Infection and Immunity · doi:10.1128/iai.52.1.6-11.1986 · Cited by 72
Roy, A., Singh, M. S., Upadhyay, P. K., & Bhaskar, S. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.01.045 · Cited by 69
Davis, M. B., Vasquez-Dunddel, D., Fu, J. L., Albesiano, E., Pardoll, D., & Kim, Y. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3262 · Cited by 67
Oral administration of xanthan gum enhances antitumor activity through Toll-like receptor 4
Takeuchi, A., Kamiryou, Y., Yamada, H., Eto, M., Shibata, K., Haruna, K., Naito, S., & Yoshikai, Y. (2009) · International Immunopharmacology · doi:10.1016/j.intimp.2009.09.012 · Cited by 65
Intradermal administration of lipopolysaccharide in treatment of human cancer
Goto, S., Sakai, S., Kera, J., Suma, Y., Soma, G., & Takeuchi, S. (1996) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050279 · Cited by 65
Lampkin, B. C., Levine, A. S., Levy, H. B., Krivit, W. A., & Hammond, D. (1985) · Cancer Research · Cited by 63
Titanium dioxide nanoparticles prime a specific activation state of macrophages
Huang, C., Sun, M., Yang, Y., Wang, F., Ma, X., Li, J., Wang, Y., Ding, Q., Ying, H., Song, H., et al. (2017) · Nanotoxicology · doi:10.1080/17435390.2017.1349202 · Cited by 61
A structure‐function approach to optimizing TLR4 ligands for human vaccines
Carter, D., Fox, C. B., Day, T. A., Guderian, J. A., Liang, H., Rolf, T., Vergara, J. A., Sagawa, Z. K., Ireton, G. C., Orr, M. T., et al. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.63 · Cited by 58
Matzner, P., Sorski, L., Shaashua, L., Elbaz, E., Lavon, H., Melamed, R., Rosenne, E., Gotlieb, N., Benbenishty, A., Reed, S. G., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29885 · Cited by 57
Taxman, D. J., MacKeigan, J. P., Clements, C. M., Bergstralh, D. T., & Ting, J. P. ‐. (2003) · PubMed · Cited by 57
Hennemann, B., Beckmann, G. K., Eichelmann, A., Rehm, A., & Andreesen, R. (1997) · Cancer Immunology Immunotherapy · doi:10.1007/pl00006671 · Cited by 55
Silverstein, M. J. (1974) · JAMA · doi:10.1001/jama.229.6.688 · Cited by 55
Hung, L.-C., Lin, C., Hung, S., Wu, B.-C., Jan, M.-D., Liou, S.-H., & Fu, S. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.03.006 · Cited by 53
Isambert, N., Fumoleau, P., Paul, C., Ferrand, C., Zanetta, S., Bauer, J., Ragot, K., Lizard, G., Jeannin, J., & Bardou, M. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-172 · Cited by 53
Julier, Z., Martino, M. M., de Titta, A., Jeanbart, L., & Hubbell, J. A. (2015) · Scientific Reports · doi:10.1038/srep08569 · Cited by 52
Singh, V., Srivastava, N., Kapoor, R., & Mittal, R. D. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.10.008 · Cited by 50
Saito, K., Yajima, T., Nishimura, H., Aiba, K., Ishimitsu, R., Matsuguchi, T., Fushimi, T., Ohshima, Y., Tsukamoto, Y., & Yoshikai, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304948200 · Cited by 49
Biochemical, physiological and clinical aspects of endotoxemia
Olson, N. C., Salzer, W. L., & McCall, C. E. (1988) · Molecular Aspects of Medicine · doi:10.1016/0098-2997(88)90024-6 · Cited by 48
Lonez, C., Irvine, K. L., Pizzuto, M., Schmidt, B. I., Gay, N. J., Ruysschaert, J., Gangloff, M., & Bryant, C. E. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1915-1 · Cited by 48
Kiselyov, A., Bunimovich-Mendrazitsky, S., & Startsev, V. (2015) · BBA Clinical · doi:10.1016/j.bbacli.2015.06.002 · Cited by 47
Mett, V. L., Komarova, E. A., Greene, K. M., Bespalov, I. A., Brackett, C. M., Gillard, B. M., Gleiberman, A. S., Toshkov, I., Aygun‐Sunar, S., Johnson, C., et al. (2017) · Oncogene · doi:10.1038/onc.2017.346 · Cited by 47
de Groot, A. M., Thanki, K., Gangloff, M., Falkenberg, E., Zeng, X., Bijnen, D. C. J. V., van Eden, W., Franzyk, H., Nielsen, H. M., Broere, F., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.02.003 · Cited by 46
Fujiwara, R., Luo, Y., Sasaki, T., Fujii, K., Ohmori, H., & Kuniyasu, H. (2015) · Pathobiology · doi:10.1159/000439404 · Cited by 46
Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703
Schmidt, M., Hagner, N., Marco, A., König-Merediz, S. A., Schroff, M., & Wittig, B. (2015) · Nucleic Acid Therapeutics · doi:10.1089/nat.2015.0533 · Cited by 46
Randomised study of immunotherapy with OK-432 in uterine cervical carcinoma
Kikkawa, F., Hawai, M., Oguchi, H., Kojima, M., Ishikawa, H., Iwata, M., Maeda, O., Tomoda, Y., Arii, Y., Kuzuya, K., et al. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90291-m · Cited by 46
Schneider, L. P., Schoonderwoerd, A., Moutaftsi, M., Howard, R. F., Reed, S. G., de Jong, E. C., & Teunissen, M. B. M. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.051 · Cited by 45
Sato, M. N., Harada, K., Yoshida, H., Yura, Y., Azuma, M., Iga, H., Bando, T., Kawamata, H., & Takegawa, Y. (1997) · APOPTOSIS · doi:10.1023/a:1026428918301 · Cited by 43
Okamoto, M., Oshikawa, T., Ohe, G., Nishikawa, H., Furuichi, S., Tano, T., Moriya, Y., Saito, M., & Sato, M. (2001) · International Immunopharmacology · doi:10.1016/s1567-5769(01)00103-5 · Cited by 43
Lee, J. M., Lee, W. H., Kay, H. Y., Kim, E., Moon, A., & Kim, S. G. (2011) · International Journal of Cancer · doi:10.1002/ijc.26075 · Cited by 42
Overcoming immune tolerance to cancer by heat shock protein vaccines.
Liu, B., DeFilippo, A. M., & Li, Z. (2002) · PubMed · Cited by 42
Non-specific immunity of BCG vaccine: A perspective of BCG immunotherapy
Iqbal, N. T., & Hussain, R. (2014) · Trials in Vaccinology · doi:10.1016/j.trivac.2014.08.002 · Cited by 40
Minev, B., Chavez, F. L., & Mitchell, M. S. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00039-4 · Cited by 37
Vaccine adjuvant materials for cancer immunotherapy and control of infectious disease
Lim, Y. T. (2015) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2015.4.1.54 · Cited by 36
Shevtsov, M. A., Kim, A. V., Samochernych, A., Romanova, I. V., Margulis, B. A., Yakovenko, I. V., Ischenko, A. M., Khachatryan, W. А., & Guzhova, I. V. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s62764 · Cited by 36
Bianchi, M. G., Allegri, M., Costa, A. L., Blosi, M., Gardini, D., Pivo, C. D., Prina‐Mello, A., Cristo, L. D., Bussolati, O., & Bergamaschi, E. (2014) · Toxicology Research · doi:10.1039/c4tx00193a · Cited by 36
Mucins and Toll-like receptors: Kith and kin in infection and cancer
Tarang, S., Kumar, S., & Batra, S. K. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.040 · Cited by 35
Roy, A., Chandra, S., Mamilapally, S., Upadhyay, P. K., & Bhaskar, S. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0756-y · Cited by 34
Boushehri, M. A. S., Abdel-Mottaleb, M. M. A., Béduneau, A., Pellequer, Y., & Lamprecht, A. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1469684 · Cited by 34
Self-citationPark, S. N., Noh, K. T., Jeong, Y.-I., Jung, I. D., Kang, H. K., Cha, G. S., Lee, S. J., Seo, J.-K., Kang, D. H., Hwang, T.-H., et al. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.14 · Cited by 33
Combinations of TLR Ligands: A Promising Approach in Cancer Immunotherapy
Stier, S., Maletzki, C., Klier, U., & Linnebacher, M. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/271246 · Cited by 32
Novel therapeutic strategies based on toll-like receptor signaling
Lawton, J. A., & Ghosh, P. (2003) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(03)00077-2 · Cited by 32
Innate immunity and cancer therapy
Maruyama, K., Selmani, Z., Ishii, H., & Yamaguchi, K. (2010) · International Immunopharmacology · doi:10.1016/j.intimp.2010.09.012 · Cited by 30
Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy
Nicodemus, C. F., Wang, L. Q., Lucas, J. A., Varghese, B., & Berek, J. S. (2010) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2009.12.001 · Cited by 29
Adanitsch, F., Shi, J., Shao, F., Beyaert, R., Heine, H., & Zamyatina, A. (2018) · Chemical Science · doi:10.1039/c7sc05323a · Cited by 29
Rudilla, F., Fayolle, C., Casares, N., Durántez, M., Arribillaga, L., Lozano, T., Villanueva, L., Pío, R., Sarobe, P., Leclerc, C., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.02.052 · Cited by 29
Kuramitsu, Y., Nishibe, M., Ohiro, Y., Matsushita, K., Yuan, L., Obara, M., Kobayashi, M., & Hosokawa, M. (1997) · Anti-Cancer Drugs · doi:10.1097/00001813-199706000-00013 · Cited by 27
Chan, E. W., Kwak, E. L., Hwang, J., Heiskala, M. K., Bourdonnaye, G. D. L., & Mita, M. M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2682-2 · Cited by 26
Lin, Y.-S., Huang, L.-D., Lin, C., Ph, H., Chen, Y.-J., Wong, F.-H., Lin, C.-C., & Fu, S.-L. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.285171 · Cited by 26
Mariani, C. L., Rajon, D. A., Bova, F. J., & Streit, W. J. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-007-9415-2 · Cited by 25
Patents for Toll-like receptor ligands as radiation countermeasures for acute radiation syndrome
Singh, V. K., & Pollard, H. B. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1064900 · Cited by 24
Fan, P., Zhang, J., Wang, B., Wu, H.-Q., Zhou, S.-X., Wang, C., Zhang, J., Tian, Y., & Wu, H. (2012) · Pancreatology · doi:10.1016/j.pan.2012.02.015 · Cited by 23
The role of adjunctive immunotherapy in superficial bladder cancer
Fujita, K. (1987) · Cancer · doi:10.1002/1097-0142(19870615)59:12<2027::aid-cncr2820591210>3.0.co;2-n · Cited by 23
Kamiryo, Y., Yajima, T., Saito, K., Nishimura, H., Fushimi, T., Ohshima, Y., Tsukamoto, Y., Naito, S., & Yoshikai, Y. (2005) · International Journal of Cancer · doi:10.1002/ijc.20934 · Cited by 21
Shi, H., Gong, C., Zhang, H., Wang, Y., Zhang, J., Luo, Z., Qian, Z., Wei, Y.-Q., & Li, Y. (2012) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2012.03.073 · Cited by 21
Koizumi, S.-I., Masuko, K., Wakita, D., Tanaka, S., Mitamura, R., Kato, Y., Tabata, H., Nakahara, M., Kitamura, H., & Nishimura, T. (2012) · Cellular Immunology · doi:10.1016/j.cellimm.2012.05.002 · Cited by 20
Triozzi, P. L., Aldrich, W. A., & Ponnazhagan, S. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.09.086 · Cited by 20
Liang, X., Kim, J. T., Lim, M., Dai, B., Yang, L., Reed, S. G., Baltimore, D., & Wang, P. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.074 · Cited by 17
Papel de los receptores toll-like en las enfermedades respiratorias
Lessmann, A. C., Juárez, C., & Plaza, V. (2009) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2009.07.011 · Cited by 15
Maito, F. L. D. M., de Souza, A. P. D., Pereira, L., Smithey, M. J., Hinrichs, D. J., Bouwer, A., & Bonorino, C. (2012) · ISRN Immunology · doi:10.5402/2012/926817 · Cited by 14
Boushehri, M. A. S., Stein, V., & Lamprecht, A. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.02.053 · Cited by 14
Self-citationA pilot study on acute inflammation and cancer: a new balance between IFN-γ and TGF-β in melanoma
Ma, Y., Sun, T., Liu, Y., Zhao, N., Gu, Q., Zhang, D., Qie, S., Ni, C., Liu, Y., & Sun, B. (2009) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-28-23 · Cited by 14
Joto, N., Akimoto, T., Someya, K., & Tohgo, A. (1995) · Cellular Immunology · doi:10.1016/0008-8749(95)80002-z · Cited by 10
Browning, R. L., Mo, X. M., Muthusamy, N., & Byrd, J. C. (2015) · Oncotarget · doi:10.18632/oncotarget.3285 · Cited by 9
INFLUENZA VIRUS AND THE INCIDENCE OF PRIMARY LUNG TUMOURS IN MICE
Campbell, J. (1940) · The Lancet · doi:10.1016/s0140-6736(00)91411-9 · Cited by 7
Licea‐Perez, H., Junnotula, V., Bowen, C. L., Fang, K., Qian, Y., & Matheny, C. J. (2018) · Analytical Methods · doi:10.1039/c8ay00571k · Cited by 7
Irradiated tumor cells of lipopolysaccharide stimulation elicit an enhanced anti-tumor immunity
Li, Y., Shen, G., Nie, W., Li, Z., Sang, Y., Zhang, B., & Wei, Y. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1721-4 · Cited by 7
Enhancement of antitumor activity of OK-432 (Picibanil) by Triton X-114 phase partitioning
Hashimoto, M., Takashige, K., Furuyashiki, M., et al. (2008) · International Immunopharmacology · doi:10.1016/j.intimp.2007.09.021 · Cited by 2
Cited by
New-age vaccine adjuvants, their development, and future perspective
Verma, S. K., Mahajan, P., Singh, N. K., Gupta, A., Aggarwal, R., Rappuoli, R., & Johri, A. K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1043109 · Cited by 190
Metadata
- Authors
- Shetab Boushehri, M. A., & Lamprecht, A.
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-09-18
- Volume
- 15
- Issue
- 11
- Pages
- 4777-4800
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2890735529
- Cited by
- 161
- References
- 181
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.